Moreover, the typical case described in methods who reached long-term (20 months) SD after treated with dasatinib also proved that ICC patient with IDH1/2 mutation had a better prognosis, even if the tumor is of advanced stage. This evidence concerns the gene IDH1 and intrahepatic cholangiocarcinoma.